Physician profile
Nicholas Kinback
NPI 1497167654
$16,362.86
in general payments reported to CMS, 2019-2025
43 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 87% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,835 · 2020: $1,214 · 2021: $2,330 · 2022: $3,084 · 2023: $3,120 · 2024: $1,705 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,695 · Travel and Lodging: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,695.49 |
| Travel and Lodging | $205.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,326.82 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Abbott Laboratories | $3,025.42 | 2019-2023 | Octrode, Proclaim |
| Medtronic, INC. | $2,906.94 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Relievant Medsystems, INC. | $1,334.96 | 2021-2023 | Intracept |
| Foundation Fusion Solutions, LLC | $886.53 | 2020-2025 | |
| Abbvie INC. | $678.31 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $426.32 | 2019-2025 | Xtampza, Belbuca |
| Lundbeck LLC | $274.68 | 2021-2024 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $195.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.79 | 2020-2025 | Relistor |
| Bioventus LLC | $184.76 | 2023-2024 | Stimrouter Implantable Kit, Durolane |
| Nevro Corp. | $181.17 | 2019-2022 | |
| Vertos Medical, INC. | $176.77 | 2023-2024 | Mild Device Kit |
| Averitas Pharma INC. | $135.06 | 2023-2025 | Qutenza |
| Globus Medical, INC. | $125.44 | 2025 | Senza |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $124.89 | 2020-2022 | |
| Curonix LLC | $117.21 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pacira Therapeutics, INC. | $109.35 | 2019 | |
| Pfizer INC. | $103.04 | 2019-2024 | |
| Medtronic USA, INC. | $91.02 | 2020 | |
| Tersera Therapeutics LLC | $74.29 | 2025 | Prialt |
| Merz Pharmaceuticals, LLC | $67.85 | 2023-2024 | Xeomin |
| Si-Bone, INC. | $64.06 | 2022-2025 | |
| Nalu Medical, INC. | $55.03 | 2025 | Nalu Neurostimulation System |
| Mml US, INC. | $54.54 | 2023 | Reactiv8 |
| Biohaven Pharmaceutical Holding Company LTD. | $54.15 | 2022 | |
| Mdd US Operations, LLC | $46.72 | 2019-2020 | |
| Valinor Pharma, LLC | $39.85 | 2023-2024 | Movantik |
| Vertex Pharmaceuticals Incorporated | $36.97 | 2024-2025 | |
| Horizon Therapeutics Plc | $35.01 | 2020 | |
| Ascensia Diabetes Care US INC. | $34.13 | 2024 | |
| Painteq LLC | $25.40 | 2024 | Painteq |
| Spinal Simplicity, LLC | $24.00 | 2024 | Ha Minuteman G3-R |
| Spr Therapeutics, INC | $22.35 | 2025 | Sprint Pns System |
| Revance Therapeutics, INC. | $21.94 | 2024 | Daxi |
| Redhill Biopharma INC. | $15.43 | 2020 | |
| Virtus Pharmaceuticals LLC | $14.48 | 2025 | Levorphanol Tartrate |
| Scilex Pharmaceuticals INC. | $14.18 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $13.97 | 2022 | |
| Trice Medical, INC. | $13.74 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $13.70 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.49 | 2025 | Euflexxa |
| Teva Pharmaceuticals USA, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Kinback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.